RESQ PHARMA Trademark

Trademark Overview

On Tuesday, May 10, 2022, a trademark application was filed for RESQ PHARMA with the United States Patent and Trademark Office. The USPTO has given the RESQ PHARMA trademark a serial number of 97403524. The federal status of this trademark filing is EX PARTE APPEAL PENDING as of Wednesday, May 8, 2024. This trademark is owned by ResQ Pharma, Inc.. The RESQ PHARMA trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development of treatments for Local Anesthetic Systemic Toxicity, Non-Opioid Drug Overdose, and Ischemic Reperfusion Injury

General Information

Serial Number97403524
Word MarkRESQ PHARMA
Filing DateTuesday, May 10, 2022
Status760 - EX PARTE APPEAL PENDING
Status DateWednesday, May 8, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

NOT AVAILABLE"PHARMA"
Goods and ServicesResearch and development of treatments for Local Anesthetic Systemic Toxicity, Non-Opioid Drug Overdose, and Ischemic Reperfusion Injury

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, May 16, 2022
Primary Code042
First Use Anywhere DateMonday, July 24, 2017
First Use In Commerce DateMonday, July 24, 2017

Trademark Owner History

Party NameResQ Pharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressChicago, IL 60612

Trademark Events

Event DateEvent Description
Friday, May 13, 2022NEW APPLICATION ENTERED
Monday, May 16, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, February 27, 2023ASSIGNED TO EXAMINER
Friday, April 7, 2023EXAMINERS AMENDMENT -WRITTEN
Friday, April 7, 2023EXAMINERS AMENDMENT E-MAILED
Friday, April 7, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, April 7, 2023EXAMINER'S AMENDMENT ENTERED
Monday, April 10, 2023NON-FINAL ACTION WRITTEN
Monday, April 10, 2023NON-FINAL ACTION E-MAILED
Monday, April 10, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, July 10, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, July 10, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, July 10, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, August 21, 2023FINAL REFUSAL WRITTEN
Monday, August 21, 2023FINAL REFUSAL E-MAILED
Monday, August 21, 2023NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, November 16, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, November 16, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Friday, February 16, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Friday, February 16, 2024EXPARTE APPEAL RECEIVED AT TTAB
Friday, February 16, 2024JURISDICTION RESTORED TO EXAMINING ATTORNEY
Friday, February 16, 2024EX PARTE APPEAL-INSTITUTED
Monday, May 6, 2024ACTION DENYING REQ FOR RECON E-MAILED
Monday, May 6, 2024NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Monday, May 6, 2024ACTION CONTINUING FINAL - COMPLETED
Thursday, November 14, 2024EXPARTE APPEAL DISMISSED - FAILURE TO FILE BRIEF

Related Keywords

pharma resq overdose drug ischemic reperfusion injury opioid toxicity treatments development local